KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Deferred Taxes (2022 - 2025)

Neogenomics (NEO) has disclosed Deferred Taxes for 4 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Deferred Taxes rose 73.14% year-over-year to $2.7 million, compared with a TTM value of $3.4 million through Dec 2025, up 9.41%, and an annual FY2025 reading of $3.4 million, up 9.41% over the prior year.
  • Deferred Taxes was $2.7 million for Q4 2025 at Neogenomics, up from -$869000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $5.7 million in Q2 2022 and bottomed at -$869000.0 in Q3 2025.
  • Average Deferred Taxes over 4 years is $2.1 million, with a median of $2.3 million recorded in 2023.
  • Peak annual rise in Deferred Taxes hit 109.05% in 2025, while the deepest fall reached 456.15% in 2025.
  • Year by year, Deferred Taxes stood at $3.3 million in 2022, then plummeted by 45.34% to $1.8 million in 2023, then fell by 14.18% to $1.6 million in 2024, then surged by 73.14% to $2.7 million in 2025.
  • Business Quant data shows Deferred Taxes for NEO at $2.7 million in Q4 2025, -$869000.0 in Q3 2025, and $993000.0 in Q2 2025.